GSK Partners with Imperial College London in $520M AI-Driven Initiative to Tackle Antimicrobial Resistance

Nov 19, 2025 18:32 CST Updated 18:32

GSK

Pharmaceutical R&D Manufacturer

Recently, multinational pharmaceutical companiesGlaxoSmithKline PLC.（GSK) announced an investment of £45 million (approximately RMB 420 million) for six major new research projects.

These projects integrate the most outstanding scientific expertise and the latest technologies, including advanced artificial intelligence, with the aim of finding new ways to slow the progress of antimicrobial resistance (AMR).

Through this collaboration, GSK will become a part of The Fleming Initiative led by Imperial College London in the UK.First Founding Partner。

All six new projects will kick off in early 2026, with full funding for three years, covering six key themes, including driving the discovery of antibiotics for Gram-negative bacterial infections, deepening understanding starting with Staphylococcus aureus to inspire vaccine research.AndCreate PredictionHow Drug-Resistant Pathogens Emerge and SpreadArtificial Intelligence Modeletc.

Multiple Technologies Applying AI to Be Open-Sourced Globally

One of the goals of the plan is to break through the defenses of Gram-negative bacteria.

Chemists, microbiologists, and AI experts from Imperial College, GSK, and Agilent collaborate to use advanced automation technology to generate novel datasets of diverse molecules, creating AI/machine learning models to enhance our ability to design antibiotics for multidrug-resistant Gram-negative infections.

These data and artificial intelligence models will be open to scientists worldwide, with the hope of accelerating the development of a new generation of antibacterial drugs.

Another challenge is, from fighting againstAspergillus着手Drive the discovery of new drugs. Currently, there are only four drugs available in this field, usually targeting the same parts within fungal cells. The new project will use artificial intelligence to identify unique vulnerabilities of fungi to support the development of novel targeted drugs.

Recommended Reading